The Myeloma Beacon™

Leave a comment

News

Resources

Links

Most Recent Comments

• Julie Shilane: Hi Carol, The following Web site lists all of the clinical trials that are currently being conducted...
• Carol Costner: Thank you for the information on MM. My husband has had a stem cell transplant, in November, 2007, and...
• julie: This blog posting has an interesting discussion about the appropriateness of using the word “cure”...
• Malcolm: It always amuses me to hear that standard line that there is not yet enough research to warrant taking the...
• L: GREAT news!!!

Subscribe

• Subscribe to our RSS feed
• Get Beacon News by Email
• Become our fan on Facebook!
• Follow us on Twitter!

News Archives

• ▼2010 (37)
  • ▼ March (5)
    • Regardless Of Prior Therapies, Velcade Is Superior Over Dexamethasone In Relapsed Multiple Myeloma Patients
    • Beacon NewsFlashes – March 9, 2010
    • Study Documents The Impact Of Age At Diagnosis On Myeloma Patient Survival
    • Genetic Risk Factors And Treatment History May Predict Response In Patients With Relapsed/Refractory Myeloma, Study Finds
    • International Effort Updates Results From Multiple Myeloma Stem Cell Transplant Trials
  • ► February (15)
    • Thalidomide As Induction And Maintenance Therapy Improves Response Rates In Multiple Myeloma Patients
    • The Top Myeloma Research Of 2009
    • Achieving Very Good Partial Response Indicates A Good Prognosis For Multiple Myeloma Patients, Study Finds
    • Beacon NewsFlashes – February 18, 2010
    • Curcumin And Multiple Myeloma: Preclinical And Early Clinical Studies Are Promising; Still Awaiting More Clinical Evidence
    • Total Therapy Regimen May Be Highly Effective In Newly Diagnosed Myeloma Patients
    • Unresponsiveness To Revlimid Or Thalidomide Indicates Poor Response To Stem Cell Transplant, Study Finds
    • Revlimid Maintenance Therapy Is Added To Multiple Myeloma Treatment Guidelines
    • Revlimid-Cyclophosphamide-Prednisone Combination May Be Highly Effective For Refractory Multiple Myeloma Patients
    • Vertebroplasty Relieves Pain And Restores Mobility In Myeloma-Related Spinal Fractures, Study Finds
    • Bone Formation And Degradation Proteins May Predict Progression Of Multiple Myeloma And Myeloma-Related Bone Disease
    • Beacon NewsFlashes – February 5, 2010
    • Addition Of Defibrotide To Melphalan-Prednisone-Thalidomide Combination Produces Fewer Side Effects In Multiple Myeloma Patients
    • Velcade-Doxil-Dexamethasone Regimen Followed By Post-Transplant Revlimid May Be A Highly Effective Treatment For Newly Diagnosed Myeloma Patients
    • Personal Perspective: Former Football Star And Young Father “Dominates” Cancer With Optimism, Information, And Support
  • ► January (17)
    • Beacon NewsFlashes – January 29, 2009
    • Post-Transplant Revlimid Therapy Increases Complete Response Rates In Multiple Myeloma Patients, Study Finds (ASH 2009)
    • Despite Side Effects, High-Dose Melphalan Remains The Most Effective Dosage In Preparation For Stem Cell Transplantation
    • Velcade Induction and Maintenance Combinations Are Highly Effective In Elderly Multiple Myeloma Patients, Study Finds (ASH 2009)
    • Beacon NewsFlashes - January 25, 2010
    • Thought Leader Perspective: Dr. Robert Kyle On Myeloma Treatments Requiring Further Study
    • Statins Reduce Acute Graft-Versus-Host Disease In Allogeneic Stem Cell Transplants, Study Finds
    • Study Compares Out-Of-Pocket Expenses For Myeloma Patients Treated With Velcade, Revlimid, Or Thalidomide (ASH 2009)
    • Beacon NewsFlashes – January 14, 2010
    • Thought Leader Perspective: Dr. Robert Kyle On Treating Multiple Myeloma
    • Celgene Plans To Seek Approval Of Revlimid As An Initial Treatment For Multiple Myeloma
    • M-CSF May Act As Powerful Prognostic Factor For Multiple Myeloma
    • Papayas, Papain and Multiple Myeloma: A Potential Adjunct Therapy That Requires Further Evaluation
    • FDA Approves Velcade’s Data Showing Survival Benefit In Newly Diagnosed Myeloma Patients
    • Revlimid May Be More Effective Than Thalidomide In Newly Diagnosed Multiple Myeloma
    • Elotuzumab In Combination With Revlimid And Dexamethasone Shows Encouraging Results In Multiple Myeloma (ASH 2009)
    • Multiple Myeloma Patients On Thalidomide At Risk For Infection Despite Preventative Medication (ASH 2009)
• ►2009 (269)
  • ► December (17)
    • Velcade-Thalidomide-Dexamethasone Treatment Is Promising For Newly Diagnosed Multiple Myeloma (ASH 2009)
    • Addition Of Thalidomide To Induction Therapy Increases Response Rates In Younger And Older Multiple Myeloma Patients (ASH 2009)
    • NPI-0052 Shows Promise In Relapsed/Refractory Multiple Myeloma (ASH 2009)
    • Novel Therapeutic Agents May Reduce Kidney Impairment In Newly Diagnosed Myeloma Patients (ASH 2009)
    • Preemptive Treatment Benefits High-Risk Smoldering Myeloma Patients, Study Finds (ASH 2009)
    • Revlimid Maintenance Therapy Significantly Extends Disease-Free Survival
    • Zolinza Combination Treatments Offer Benefit For Multiple Myeloma Patients (ASH 2009)
    • Perifosine Combination Therapy Is Promising For Relapsed And Refractory Multiple Myeloma (ASH 2009)
    • Revlimid May Set “New Standard” For Treating Newly Diagnosed Multiple Myeloma In Elderly Patients (ASH 2009)
    • Tanespimycin-Velcade Combination Proves Highly Effective In Multiple Myeloma Patients (ASH 2009)
    • Survival Greater Than 10 Years In Multiple Myeloma Is Related To Longer Treatment Duration (ASH 2009)
    • Beacon NewsFlashes - December 8, 2009
    • Velcade-Dexamethasone Combination Regimen Increases Survival In Newly Diagnosed High Risk Myeloma Patients (ASH 2009)
    • Carfilzomib Is Effective For Multiple Myeloma – Part 2: Treatment Of Specific Patient Groups (ASH 2009)
    • Carfilzomib Is Effective For Multiple Myeloma – Part 1: As A Single Agent Or In A Combination Therapy (ASH 2009)
    • Beacon NewsFlashes - December 3, 2009
    • Velcade-Melphalan-Prednisone-Thalidomide (VMPT) Treatment Is Highly Active In Elderly Myeloma Patients (ASH 2009)
  • ► November (15)
    • Velcade-Torisel Combination Proves Highly Effective In Multiple Myeloma Patients (ASH 2009)
    • Serum Albumin Levels Indicate Severity Of Multiple Myeloma
    • New Velcade Combination Therapy Effective For Newly Diagnosed Myeloma Patients (ASH 2009)
    • Treatment Trends For Multiple Myeloma – Part 3: Options For Elderly Multiple Myeloma Patients
    • Single-Agent Actimid And Combination Actimid-Dexamethasone Regimens Are Promising Treatments For Relapsed Myeloma (ASH 2009)
    • Beacon NewsFlashes – November 23, 2009
    • Torisel Achieves Little Response In Relapsed Multiple Myeloma Patients
    • Myeloma Research To Be Presented At The American Society of Hematology’s 51st Annual Meeting (ASH 2009)
    • Vitamin C Inhibits Anti-Myeloma Activity Of Velcade
    • Beacon NewsFlashes – November 13, 2009
    • Treatment Trends For Multiple Myeloma – Part 2: Allogeneic Stem Cell Transplants
    • The H1N1 Swine Flu Vaccine And Multiple Myeloma: A Comprehensive Review
    • Beacon NewsFlashes – November 6, 2009
    • Lawsuit Filed To Overturn Ban On Payment For Bone Marrow Donations
    • Treatment Trends For Multiple Myeloma – Part 1: Autologous Stem Cell Transplants
  • ► October (19)
    • Beacon NewsFlashes – October 30, 2009
    • Velcade-Doxil-Dexamethasone Combination Treatment Is Highly Effective In Newly Diagnosed Multiple Myeloma Patients
    • Thalidomide Improves Outcome Of Double Stem Cell Transplants In Younger Myeloma Patients
    • Study Shows Higher Survival With Revlimid And Low-Dose Dexamethasone Than Revlimid And High-Dose Dexamethasone In Multiple Myeloma Patients
    • Retreatment With Velcade As A Treatment Option For Relapsed Myeloma Patients
    • Phase 2 Clinical Trial Offers Positive Results For A Steroid-Free Multiple Myeloma Treatment
    • Beacon NewsFlashes – October 23, 2009
    • Study Shows Benefits Of Vesselplasty In The Treatment Of Spinal Fractures
    • New Recommendations Issued On Stem Cell Collection And Treatment With Revlimid, Thalidomide, And Velcade
    • Multiple Myeloma Study Finds “Complete Response” Is Generally Correlated With Survival
    • Myeloma Patients Are At Increased Risk For Blood Clots, Particularly Patients Using Revlimid Or Thalidomide
    • Beacon NewFlashes - October 15, 2009
    • Onyx Pharmaceuticals To Acquire Proteolix, Developer Of Carfilzomib
    • New Directory Could Assist In Myeloma Treatment
    • Beacon NewsFlashes – October 8, 2009
    • Carfilzomib Is Highly Active In Relapsed Myeloma Patients
    • Immune System Cells Protect Myeloma Cancer Cells, Study Finds
    • TIMP-1 Biomarker Predicts Myeloma Progression And Survival
    • Beacon NewsFlashes – October 2, 2009
  • ► September (19)
    • Taking Vitamin D And Calcium Supplements Together May Prevent Cancer
    • New Drug Enters Phase 2 Clinical Trial For Stem Cell Collection For Blood Cancer Patients
    • Second Dose Of Aloxi Further Reduces Chemotherapy-Induced Nausea In Cancer Patients
    • New Study Highlights Myeloma Treatment Infection Risks
    • Beacon NewsFlashes – September 23, 2009
    • Study On Myeloma Diagnosis Techniques Favors Newer Imaging Methods
    • Phase 3 Trial Indicates Denosumab Delays Skeletal Related Events In Cancer Patients
    • Study Shows Mozobil Induces Mobilization Of Stem Cells But Not Myeloma Tumor Cells
    • Study Supports Use Of Kyphoplasty For Multiple Myeloma Patients
    • Beacon NewsFlashes – September 16, 2009
    • Swine Flu Vaccinations Recommended For Multiple Myeloma Patients
    • Beacon NewsFlashes – September 12, 2009
    • Red Wine, Resveratrol, And Multiple Myeloma: The Evidence Is Promising, But Needs Further Study
    • Multiple Myeloma Conferences To Be Held In Hawaii, Arizona, Canada, And Greece
    • FDA To Review Velcade-Melphalan-Prednisone Regimen
    • Combination Actimid And Dexamethasone Regimen Is Promising For Relapsed And Refractory Myeloma Patients
    • Scientists Find A Protein That Causes Resistance To Velcade Treatment
    • Macrophages May Contribute To Survival Of Multiple Myeloma Cells
    • Beacon NewsFlashes – September 1, 2009
  • ► August (17)
    • Personal Perspective: Engineer With Myeloma Finds Hope Through Cancer Support Group And Blogs
    • Beacon NewsFlashes – August 27, 2009
    • Pathologic Fractures In Bisphosphonate-Treated Patients Not Indicative Of Myeloma Progression
    • Personal Perspective: The Adventures Of Cancer Girl
    • Eradicating H. pylori Infection Not Linked To MGUS Regression
    • Beacon NewsFlashes – August 20, 2009
    • Phase 1 Clinical Trial Studies Velcade And Zolinza In Myeloma Patients
    • Kidney Failure In Multiple Myeloma Patients - Part 4: Hemodialysis
    • Beacon NewsFlashes - August 14, 2009
    • Skipped Bone Marrow Exams Give False Positives In Multiple Myeloma Clinical Trials
    • Multiple Myeloma Vaccine Shows Promise In Mice
    • High Incidence Of Multiple Myeloma In World Trade Center Responders
    • Research Shows Velcade’s Possible Mechanism of Action
    • Shortage of Clinical Trial Participants Hinders War On Cancer
    • Beacon NewsFlashes – August 6, 2009
    • Perifosine Advances To Phase 3 Multiple Myeloma Clinical Trial
    • Beacon NewsFlashes - August 3, 2009
  • ► July (20)
    • Study Shows Toxicity Of Second Transplant For Myeloma Patients
    • Clinical Trials Start For A Pre-Transplant Treatment
    • Researchers Sequence Full Multiple Myeloma Tumor Genome
    • Beacon NewsFlashes – July 28, 2009
    • Multiple Myeloma Patients’ Relatives Are Twice As Likely To Have MGUS
    • Dr. Sagar Lonial Provides Insight Into High-Risk Myeloma
    • Vitamin D Deficiency May Cause Skeletal Complications In Multiple Myeloma Patients
    • Clinical Trial Supports Revlimid As First-Line Therapy For Myeloma
    • Anti-DKK1 Antibody As New Treatment For Myeloma Bone Disease
    • Beacon BreakingNews - Clinical Trial Supports Revlimid As First-Line Therapy For Myeloma
    • Beacon NewsFlashes – July 21, 2009
    • Kidney Failure In Multiple Myeloma Patients – Part 3: Time and Care Commitments
    • Dental Exams Recommended Before Bisphosphonate Therapy
    • Kidney Failure In Multiple Myeloma Patients - Part 2: Treatment
    • Beacon NewsFlashes -- July 14, 2009
    • Quality Of Life Warrants More Consideration In Multiple Myeloma Treatment Recommendations
    • Study Examines Quality Of Life After Stem Cell Transplantation
    • Beacon NewsFlashes – July 8, 2009
    • Vegetarians Less Likely To Develop Multiple Myeloma
    • Revlimid As Initial Myeloma Therapy Inhibits Stem Cell Collection
  • ► June (17)
    • Beacon NewsFlashes — June 30, 2009
    • Kidney Failure In Multiple Myeloma Patients - Part 1: Overview
    • XRCC5 Gene Variants Associated With Greater Blood Clot Risk During Thalidomide Treatment
    • Stem Cell Transplants May Improve Kidney Function of Myeloma Patients
    • Beacon NewsFlashes -- June 24, 2009
    • U.K. Finalizes Revlimid Therapy Guidelines
    • Canadian Authorities Confiscating Thalidomide At Border
    • Velcade Plus Dexamethasone Produces Robust, Yet Short-Lived, Response In Myeloma Patients
    • Beacon NewsFlashes - June 15, 2009
    • Revlimid Boosts Immune System Of Some Myeloma Patients
    • Beacon NewsFlashes - June 9, 2009
    • Study Shows Acute Kidney Failure Can Be Reversed By Velcade-Dexamethasone-Doxorubicin In Multiple Myeloma
    • Total Therapy Emerges As Prospect For Multiple Myeloma Cure
    • Myeloma Precursor MGUS Linked To Pesticide Use
    • Beacon NewsFlashes – June 3, 2009
    • Expert Panel Recommends European Approval Of Mozobil
    • Study Examines Romidepsin-Velcade Combination Treatment In Myeloma Patients (ASCO 2009)
  • ► May (23)
    • ONJ As A Prognostic Factor In Myeloma Patients Treated With Zometa (ASCO 2009)
    • Beacon NewsFlashes - May 29, 2009
    • Nexavar Shows No Effect In Phase 2 Study (ASCO 2009)
    • MMRF Announces Research Collaboration With The Broad Institute
    • Clinical Trial Shows Ginger Reduces Nausea (ASCO 2009)
    • New Hemodialysis Procedure Improves Health Of Multiple Myeloma Patients
    • IGF-1: An Important Myeloma Growth Factor
    • Trial Investigates Effects Of Tanespimycin-Velcade Combination Treatment (ASCO 2009)
    • Autologous Stem Cell Transplant Therapy With Velcade-Revlimid Or Velcade-Thalomid in New Multiple Myeloma Patients (ASCO 2009)
    • Phase 3 Study Shows High Response Rates For Four-Drug Combination (ASCO 2009)
    • Beacon NewsFlashes - May 18, 2009
    • Formaldehyde Exposure Linked To Increased Risk Of Multiple Myeloma
    • ASCO 2009 - 45th Meeting Of The American Society Of Clinical Oncology Only Two Weeks Away
    • Myeloma Patients In Canada Smuggle Low-Priced Thalidomide
    • Beacon NewsFlashes – May 13, 2009
    • Mozobil With Neupogen Increases Stem Cell Harvest Efficiency
    • Iowa Firefighters And Police Officers To Benefit From Cancer Bill
    • Durie-Salmon Staging System And International Staging System Compared In Patients After ASCT
    • Socioeconomic Standing May Affect Survival For Swedish Myeloma Patients
    • Beacon NewsFlashes – May 9, 2009
    • Current Use Of Velcade In Newly Diagnosed Myeloma Patients
    • Study Projects Rising Cancer Rates In The United States
    • New Hampshire Legislature Approves Medical Marijuana Bill
  • ► April (29)
    • Study Finds Lack Of Evidence For Link Between Firefighting And Cancer
    • Beacon NewsFlashes — April 28, 2009
    • The Access To Cancer Trials Act Of 2009 Brought Before Congress
    • Beacon NewsFlashes — April 27, 2009
    • NICE Recommends Revlimid For Multiple Myeloma Patients In U.K.
    • Melphalan-Prednisone Survival Rates Higher Than Thalidomide-Dexamethasone In Elderly
    • Study Measures Effects Of Novel Drugs On Myeloma Patients With Chromosomal Abnormalities
    • Beacon NewsFlashes – April 22, 2009
    • Long-Term Outcome Of Combination Auto/Allo Stem Cell Transplant Treatment Reported
    • Beacon NewsFlashes – April 20, 2009
    • Beacon NewsFlashes – April 17, 2009
    • New Revlimid Warning For Patients With Impaired Kidney Function
    • Gene Identification Could Lead To Better Treatment Options For Multiple Myeloma
    • High-Risk Myeloma Patients Show Overall Lower Progression-Free Survival With Revlimid-Dexamethosone Therapy
    • Thalidomide Plus Prednisone Shown To Improve Survival After ASCT
    • Beacon NewsFlashes – April 13, 2009
    • Beacon NewsFlashes – April 10, 2009
    • IMW 2009 - Physicians Debate "Cure Versus Control" Of Myeloma
    • IMW 2009 – Physicians Discuss Induction Therapy For Non-Transplant Candidates
    • IMW 2009 - Elotuzumab And Panobinostat Clinical Trials With Velcade
    • CMS Decides To Cover PET Scans For Myeloma Patients
    • Addition Of Second Drug Could Dramatically Improve Velcade Response
    • Beacon NewsFlashes – April 7, 2009
    • Tools For Diagnosing Multiple Myeloma / Part 4: Specialized Studies
    • Growth In Off-Label Drug Use Slows
    • Blood Cancers Forum Focuses On Importance Of Clinical Trials
    • IMW 2009 – Physicians Discuss Upfront And Induction Therapy For Transplant Candidates
    • Beacon NewsFlashes – April 1, 2009
    • Medicare Expands Coverage Of Off-Label Uses Of Cancer Drugs – Part 2: Medicare-Approved Compendia
  • ► March (31)
    • New Gene Implicated In Multiple Myeloma And Other Cancers
    • Kennedy Renews War On Cancer
    • The MMRF Marathon And Half Marathon Program Seeks Runners
    • Beacon NewsFlashes – March 29, 2008
    • Beacon NewsFlashes - March 27, 2009
    • Genetic Blood Tests Could Soon Identify Multiple Myeloma And Other Disorders
    • Beacon NewsFlashes – March 25, 2009
    • Tools For Diagnosing Multiple Myeloma / Part 3: Prognostic Evaluation
    • Beacon NewsFlashes – March 23, 2009
    • Beacon NewsFlashes – March 21, 2009
    • Beacon NewsFlashes – March 20, 2009
    • Scotland Expected To Improve Patient Access To New Cancer Therapies
    • Beacon NewsFlashes - March 16, 2009
    • IMW 2009 - Physicians Discuss New Drugs For Relapsed/Refractory Patients
    • Beacon NewsFlashes - March 14, 2009
    • Tools For Diagnosing Multiple Myeloma / Part 2: End-Organ Damage Evaluation
    • New Myeloma Drugs Target Different Mechanisms: Misfolded Proteins
    • Current Information On Response Criteria For Multiple Myeloma
    • IMW 2009 - Physicians Discuss Symptom Management Strategies
    • Beacon NewsFlashes - March 10, 2009
    • Managing The Side Effects Of Revlimid And Velcade
    • Beacon NewsFlashes – March 9, 2009
    • Current Information On Risk Stratification In Multiple Myeloma
    • New Myeloma Drugs Target Different Mechanisms: Signaling Pathways
    • Beacon NewsFlashes - March 6, 2009
    • IMW 2009 - Waldenstrom's Award Goes To IMF Co-Founder And Chairman
    • Blood Disorder MGUS Precedes Most Cases Of Multiple Myeloma
    • The MMRF Awards $1 Million For Promising Early-Stage Drug Development
    • Beacon NewsFlashes – March 2, 2009
    • IMW 2009 – Consensus On Risk Stratification In Multiple Myeloma
    • Beacon NewsFlashes - March 1, 2009
  • ► February (32)
    • Current Information On Staging Multiple Myeloma
    • New Myeloma Drugs Target Different Mechanisms Of Action: Cell Surface Receptors
    • Canadian Survey Highlights Myeloma Awareness And Access To Treatment
    • Beacon NewsFlashes - February 24, 2009
    • IMW 2009 - Physicians Offer Standardized Guidelines For Diagnosing Suspected Multiple Myeloma
    • Radiation Not Linked To MGUS Progression To Multiple Myeloma
    • Beacon NewsFlashes - February 23, 2009
    • IMW 2009 - Doctors Clarify Standards For Clinical Trial Reporting
    • Physicians Perform First Bone Marrow Transplant At Public Hospital In West Bengal, India
    • Health Care-Associated MRSA In Decline
    • XII International Myeloma Workshop Begins Next Week
    • Clarifications And Updates In Diagnosis Criteria Of Multiple Myeloma
    • Tools For Diagnosing Multiple Myeloma / Part 1: Diagnostic Evaluation
    • Beacon NewsFlashes - February 18, 2009
    • Bill Helps Oregon Firefighters Get Cancer Coverage
    • Medicare Expands Coverage Of Off-Label Uses Of Cancer Drugs – Part 1
    • MMRF And LLS Grant $500,000 For Study Of The Multiple Myeloma Stem Cell
    • The American Society Of Clinical Oncology Provides A Financial Guide To Cancer Care
    • Long-Term Survival Estimates Increase For Young Multiple Myeloma Patients
    • Researchers Identify Novel Tumor Feeding Mechanism
    • Beacon NewsFlashes - February 11, 2009
    • Beacon NewsFlashes - February 11, 2009
    • Leukemia & Lymphoma Society And Women’s Running Magazine Join Forces To Launch New Women’s Half Marathon
    • Regulations And The Rising Cost Of Cancer Drugs
    • MMRF Is The Official Charity Of The Rite Aid Cleveland 5K
    • Beacon NewsFlashes - February 6, 2009
    • Green Tea Blocks Effectiveness Of Velcade Treatment
    • Beacon NewsFlashes - February 4, 2009
    • Study Finds No Link Between Hair Dyes And Myeloma
    • Beacon NewsFlashes – February 2, 2009
    • Deal Brings Revlimid To U.K. Myeloma Patients
    • Beacon NewsFlashes - February 1, 2009
  • ► January (30)
    • Preventive Measures Can Reduce Osteonecrosis Of The Jaw In Patients Taking Zometa
    • Fruits And Vegetables Do Not Decrease Risk of Multiple Myeloma
    • Beacon NewsFlashes – January 28, 2008
    • FJC Awards $1 Million Grant To Institute For Myeloma And Bone Cancer Research
    • Blood Cancers The Subject Of Seminar At University Of Chicago Medical Center
    • Beacon NewsFlashes – January 26, 2009
    • Radiation Therapy, Vertebroplasty, And Kyphoplasty: Three Treatments For Myeloma Bone Disease
    • Scientists Develop Serum Immunoglobulin Free Light Chain Assay For Early Myeloma Diagnosis
    • Chemical Used In Rubber Synthesis Increases Risk Of Myeloma
    • New Drug for Preventing Nausea and Vomiting During Chemotherapy
    • Beacon NewsFlashes – January 21, 2009
    • MMRF Meeting Discusses Prognosis And Treatments For Myeloma Patients
    • Multiple Myeloma Treatment Approaches And Objectives
    • Phase 3 Zolinza-Velcade Trial Opening Soon
    • New Clinical Trials Combine Zolinza And Velcade For Multiple Myeloma Treatment
    • Beacon NewsFlashes - January 19, 2009
    • Thalomide Approved For First-Line Treatments In Scotland
    • Treatment In Elderly Multiple Myeloma Patients
    • Tandem Autologous Stem Cell Transplantation Compared To Single Autologous Stem Cell Transplantation
    • Managing Steroid-Related Side Effects In Myeloma Patients
    • MMRF Meeting Discusses Racial Disparities In Multiple Myeloma
    • Novel Therapies For Myeloma Bone Disease
    • Beacon NewsFlashes – January 13, 2009
    • Bisphosphonate Treatment For Myeloma Bone Disease
    • Beacon NewsFlashes – January 9, 2009
    • Phase 1 Clinical Trial Of CX-4945 Begins In Cancer Patients
    • U.K. To Expand Access To Drugs For Terminally Sick
    • Anti-Cancer Drug Zolinza Shows Potential In Myeloma
    • Beacon NewsFlashes – January 5, 2009
    • Osteoporosis Drug Increases Risk Of Esophageal Cancer And Jaw Disease
• ►2008 (65)
  • ► December (34)
    • Beacon NewsFlashes - December 30, 2008
    • Cancer Drugs To Cost More Under Medicare Plans
    • Leading Oncologists Present Clinical Research Advances in 2008
    • Clinical Trials Begin For New Form Of Radiotherapy
    • Skeletal Imaging For Bone Lesions In Multiple Myeloma Patients
    • ASH 2008 - New Induction Therapy for Elderly Patients
    • ASH 2008 - High Response Rate for Revlimid-Velcade-Dexamethasone Treatment in Phase 2 Studies
    • Diana Krall To Host Fundraiser Benefiting Blood Cancer Patients
    • FDA Approves Mozobil For Myeloma Patients Preparing For Stem Cell Transplants
    • Treatment In Young Multiple Myeloma Patients
    • ASH 2008 – Results Of Tandem Stem Cell Treatment For Newly Diagnosed Myeloma Patients
    • ASH 2008 - Ongoing Phase 2 Clinical Trials For Carfilzomib Show Promising Results
    • ASH 2008 - Carfilzomib, A Novel Drug Related To Velcade, Reduces Peripheral Neuropathy
    • ASH 2008 – Trial Results Compare Multiple Myeloma Transplantation Procedures
    • ASH 2008 – Venous Thrombotic Events In Newly Diagnosed Myeloma Patients Decrease Overall Survival
    • Beacon NewsFlashes - December 16, 2008
    • Impact of PET Scans Consistent Across All Types of Cancer
    • ASH 2008 – Perifosine Effective Against Multiple Myeloma In Combination With Dexamethasone-Revlimid And Dexamethasone-Velcade
    • Beacon NewsFlashes - December 12, 2008
    • ASH 2008 – Clinical Trial Update for Velcade-Thalidomide-Dexamethasone With Autologous Stem Cell Transplantation In Newly Diagnosed Myeloma Patients
    • Multiple Myeloma Research Consortium Announces Center Of The Year
    • ASH 2008 – Updated Velcade-Melphalan-Prednisone Trial Results For Newly Diagnosed Myeloma Patients
    • Deep Vein Thrombosis Risk Higher In Multiple Myeloma
    • ASH 2008 - VDD Initial Treatment More Effective Than TD Initial Treatment
    • ASH 2008 - Actimid-Dexamethasone Combination Highly Effective In Treating Relapsed And Refractory Multiple Myeloma
    • ASH 2008 - Scientists Reveal Promising Four-Drug Regimen For Newly-Diagnosed Myeloma Patients
    • Phase 3 Trials Of Hsp90 Inhibitors In Cancer Patients Underway
    • Outpatient Stem Cell Transplant For Multiple Myeloma
    • New Therapies Show Promise For Multiple Myeloma Treatment
    • Beacon NewsFlashes - December 5, 2008
    • Multiple Myeloma Survivors Honored At 2008 ASH Meeting
    • 50th Annual Meeting Of The American Society Of Hematology Only Days Away
    • Beacon NewsFlashes – December 2, 2008
    • Physicians Discuss Past Progress And Future Goals In Treating Multiple Myeloma
  • ► November (30)
    • Holiday Party In Las Vegas To Benefit The Leukemia & Lymphoma Society
    • Parade In New Zealand To Benefit Families Living With Multiple Myeloma
    • U.S. Cancer Incidence And Mortality Rates Fall For The First Time
    • Revlimid Combination Effective Against Relapsed And Refractory Myeloma
    • Beacon NewsFlashes - November 23, 2008
    • Increased Risk Of Blood Clotting Reported In Patients Treated With Avastin
    • IMF Continues Support Of Peter Boyle Memorial Fund
    • Long-Term Exposure To Benzene Appears To Increase Risk Of Multiple Myeloma
    • New Technique Shows Improved Detection Of Myeloma Tumor Cells After Treatment
    • IMF Announces New Global Research Partnership To Study Multiple Myeloma Biomarkers
    • Beacon NewsFlashes - November 17, 2008
    • Treatment With Folic Acid And B Vitamins Has Little Effect On Multiple Myeloma Risk Among Women
    • Beacon NewsFlashes - November 14, 2008
    • Link Between Gene Variation And Myeloma Survival
    • ImmunoCellular Therapeutics Presents Data Showing Immune Response On Cancer Stem Cells
    • Occupation And Chemical Exposure Linked To Multiple Myeloma
    • African-Americans Still At Higher Risk Of Developing Multiple Myeloma
    • Beacon NewsFlashes - November 11, 2008
    • CIGNA, Leukemia & Lymphoma Society Promote Financial Aid Program
    • Beacon NewsFlashes - November 7, 2008
    • International Myeloma Foundation Calls For Patient Access To Newest Myeloma Treatments
    • Beacon NewsFlashes – November 6, 2008
    • Antibody Treatment In Mice Shows Antitumor Activity
    • Prolexys Pharmaceuticals Raises $20 Million to Further Work on Anti-tumor Molecule
    • Immune System Cells Show Promise As Myeloma Therapy
    • FDA Approves Cephalon's Treanda for Second Cancer Indication
    • MMRF Raises Over $1.5 Million In Annual Fall Gala
    • Incidence Of Multiple Myeloma In Women May Correlate With Height, Not Obesity
    • England And Wales May Halt Funding For Revlimid
    • Scientist Receives $720,000 Grant To Research New Myeloma Drug Targets
  • ► October (1)
    • A New Beacon For The Multiple Myeloma Community